C4 Therapeutics, Inc. (CCCC) Is Up 2.65% in One Week: What You Should Know
Does C4 Therapeutics, Inc. (CCCC) have what it takes to be a top stock pick for momentum investors? Let's find out.
CCCC - C4 Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$7.00
DETAILS
HIGH:
$7.00
LOW:
$7.00
MEDIAN:
$7.00
CONSENSUS:
$7.00
UPSIDE:
67.47%
Stock News
C4 Therapeutics, Inc. (CCCC) Discusses Evolving Multiple Myeloma Treatments and the Role of IKZF1/3 Degraders Including Cemsidomide Transcript
C4 Therapeutics, Inc. (CCCC) Discusses Evolving Multiple Myeloma Treatments and the Role of IKZF1/3 Degraders Including Cemsidomide Transcript
Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?
Here is how C4 Therapeutics, Inc. (CCCC) and Clene Inc. (CLNN) have performed compared to their sector so far this year.
C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population
At the 100 µg Recommended Phase 2 Dose (RP2D), Cemsidomide Demonstrated a 53% Overall Response Rate, Including Complete Responses and Minimal Residual Disease (MRD) Negative Status
C4 Therapeutics "Buy" On Cemsidomide Advancement And Competitor's Positive Readout
I initiate C4 Therapeutics (CCCC) with a "Buy rating," driven by robust progress of its next-gen CELMoD cemsidomide in relapsed/refractory multiple myeloma. Company's lead program advances through phase 2 MOMENTUM and phase 1b combination studies, with key data catalysts expected at EHA 2026 and throughout 2026–2027. Strong financial position with $268.3M cash as of March 2026 supports operations into 2028, enabling continued pipeline expansion and clinical execution.
C4 Therapeutics (CCCC) Upgraded to Buy: What Does It Mean for the Stock?
C4 Therapeutics (CCCC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
C4 Therapeutics to Participate in Upcoming Conferences
WATERTOWN, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today announced that C4T management will participate in the upcoming conferences.
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
WATERTOWN, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the independent directors serving on the Organization, Leadership and Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase 85,480 shares of the Company's common stock to one new employee (the “Inducement Grant”), with the grant made on May 18, 2026 (the “Grant Date”). The Inducement Grant was granted as a material inducement to this individual entering employment with C4T in accordance with Nasdaq Listing Rule 5635(c)(4).
Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?
Here is how C4 Therapeutics, Inc. (CCCC) and Contineum Therapeutics, Inc. (CTNM) have performed compared to their sector so far this year.
C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Lags Revenue Estimates
C4 Therapeutics, Inc. (CCCC) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to a loss of $0.37 per share a year ago.
C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
WATERTOWN, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today reported financial results for the first quarter ended March 31, 2026, as well as recent business highlights.
C4 Therapeutics, Roche expand partnership with new cancer deal worth over $1 billion
C4 Therapeutics said on Thursday it has entered into a deal focused on research and development of a type of cancer drug with Swiss drugmaker Roche that could be worth more than $1 billion.
C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)
Agreement Focused on Developing DACs With Payloads For Two Oncology Targets, With an Option for a Third Target C4T to Develop Degraders With Payload Properties; Roche to Conjugate Payloads to Targeted Antibodies C4T to Receive $20 Million Upfront Payment and Eligible to Receive Over $1 Billion in Discovery, Development and Commercial Milestones, in Addition to Future Royalties WATERTOWN, Mass., April 09, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science today announced that it has entered into a new collaboration agreement with Roche (SIX: RO, ROP; OTCQX: RHHBY) to advance research in the emerging degrader-antibody conjugate (DAC) modality.
C4 Therapeutics, Inc. (NASDAQ:CCCC) Short Interest Up 58.8% in March
C4 Therapeutics, Inc. (NASDAQ: CCCC - Get Free Report) was the target of a large increase in short interest during the month of March. As of March 13th, there was short interest totaling 13,534,910 shares, an increase of 58.8% from the February 26th total of 8,520,947 shares. Based on an average daily volume of 3,621,849 shares,
Is C4 Therapeutics (CCCC) Stock Outpacing Its Medical Peers This Year?
Here is how C4 Therapeutics, Inc. (CCCC) and Align Technology (ALGN) have performed compared to their sector so far this year.
C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple Myeloma
Novel Combination Regimen Positions Cemsidomide for Use in Earlier Lines of Therapy Novel Combination Regimen Positions Cemsidomide for Use in Earlier Lines of Therapy
C4 Therapeutics, Inc. (CCCC) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
C4 Therapeutics, Inc. (CCCC) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
C4 Therapeutics: Cemsidomide Progress Keeps The Long-Term Thesis Intact
C4 Therapeutics delivered strong 4Q25 results, with revenue up 111.5% YoY and operating expenses tightly controlled. CCCC's lead asset, cemsidomide, advanced into a Phase 2 registrational trial for relapsed/refractory multiple myeloma, targeting a large, growing TAM. Cash position strengthened to $297.1M, extending operational runway through 2028 and supporting continued pipeline investment.
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
WATERTOWN, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the independent directors serving on the Organization, Leadership and Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase 85,480 shares of the Company's common stock to one new employee (the “Inducement Grant”), with the grant made on March 9, 2026 (the “Grant Date”). The Inducement Grant was granted as a material inducement to this individual entering into employment with C4T in accordance with Nasdaq Listing Rule 5635(c)(4).
C4 Therapeutics Maps Accelerated Approval Path for Myeloma Drug Cemsidomide at TD Cowen Conference
C4 Therapeutics (NASDAQ: CCCC) used a presentation at TD Cowen's 46th Annual Healthcare Conference to outline its near- and mid-term clinical plans, emphasizing its lead multiple myeloma program cemsidomide and a development strategy aimed at potential accelerated approval pathways. Focus on targeted protein degradation and a lead myeloma program Chief Executive Officer Andrew Hirsch described C4
Price Targets
C4 Therapeutics (CCCC) PT Raised to $7 at Barclays
$7.00
(was $2.81)
Etzer Darout
·
Barclays
C4 Therapeutics price target lowered to $5 from $10 at Barclays
$5.00
(was $2.26)
Barclays
C4 Therapeutics price target raised to $10 from $5 at Wells Fargo
$10.00
(was $2.80)
Derek Archila
·
Wells Fargo
C4 Therapeutics price target raised to $10 from $8 at Barclays
$10.00
(was $3.16)
Etzer Darout
·
Barclays
C4 Therapeutics initiated with an Overweight at Barclays
$8.00
(was $3.41)
Barclays
C4 Therapeutics upgraded to Overweight from Equal Weight at Stephens
$6.00
(was $3.57)
Sudan Loganathan
·
Stephens
C4 Therapeutics upgraded to Overweight from Equal Weight at Wells Fargo
$12.00
(was $4.31)
Derek Archila
·
Wells Fargo
BMO Capital Reiterates Outperform Rating on C4 Therapeutics (CCCC)
$20.00
(was $6.87)
Etzer Darout
·
BMO Capital
Wells Fargo Maintains Equal-Weight on C4 Therapeutics, Lowers Price Target to $9
$9.00
(was $6.31)
Wells Fargo
Credit Suisse Initiates Coverage On C4 Therapeutics with Underperform Rating, Announces Price Target of $10
$10.00
(was $8.85)
Credit Suisse
C4 Therapeutics (CCCC) Stock: $15 Price Target From BofA
$15.00
(was $8.01)
Chi Fong
·
Bank of America Securities